Current status of the HIBMC and results of representative diseases

Journal Article · Sat Jul 25 00:00:00 EDT 2009 · AIP Conference Proceedings

DOI:https://doi.org/10.1063/1.3204552· OSTI ID:21344336

Murakami, Masao; Demizu, Yusuke; Niwa, Yasue; Miyawaki, Daisuke; Terashima, Kazuki; Arimura, Takeshi; Mima, Masayuki; Maeda, Takuya; Akagi, Takashi; Hishikawa, Yoshio; Abe, Mitsuyuki ^[1]; Nagayama, Shinichi; Baba, Masashi ^[1]

---

1. Department of Radiology, Hyogo Ion Beam Medical Center (HIBMC) (Japan)

The proton radiotherapy (PRT) has been spreading, since 1990 when 250 MeV proton beams with rotation gantry was developed for medical use. On the other hand, carbon-ion radiotherapy (CRT) that has both physical and biological features is available at 4 facilities in the world. HIBMC is the only facility to be able to use both particles. From Apr 2001 to Dec 2008, 2486 patients were treated with PRT in 2030 patients or with CRT in 456. Treatment to the Head and Neck (H and N: in 405 patients), the lung (245), the liver (371), and the prostatic carcinoma (1059) was a major subject. The 2-year local control rates is 72% in H and N (n = 163, T1:9, T2:18, T3:36, T4:79, malignant melanoma 48, adenoid cystic carcinoma 35, squamous cell carcinoma (SCC) 32, adenocarcinoma 14, others 34), 88% in lung (n = 116, T1:59, T2:42, T3:4, T4:6, SCC 30, adenocarcinoma 59, others 27), and 89% in liver cancer (n = 153, Proton: 130, carbon: 23). Biochemical disease free 3-year survival of 291 prostate cancer is 100% in 9 patients with initial prostate-specific antigen (PSA) level < = 4 ng/ml, 99% in 140 with PSA 4.1-10 ng/ml, 90% in 71 with PSA 10.1-20 ng/ml, and 79% in 71 with PSA>20 ng/ml. These results are excellent comparable or superior to those of surgery. Thus, particle therapy is sophisticated radiotherapy, however the only problem to prohibit the progress is high costs for construction and maintenance. Facilities at which both proton and carbon ion beams can be used, including the HIBMC, have to investigate the differential use. We started clinical randomized trial to compare both ion beams, and started biological examinations in a project aiming at the development of a laser driven proton radiotherapy. We stated about the current status of the HIBMC and the results of representative diseases.

• OSTI ID: 21344336
• Journal Information: AIP Conference Proceedings, Vol. 1153, Issue 1; Conference: 2. international symposium on laser-driven relativistic plasmas applied to science, industry and medicine, Kyoto (Japan), 19-23 Jan 2009; Other Information: DOI: 10.1063/1.3204552; (c) 2009 American Institute of Physics; ISSN 0094-243X
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIGENS
CARBON IONS
CLINICAL TRIALS
COMPARATIVE EVALUATIONS
HEAD
ION BEAMS
LIVER
LUNGS
MELANOMAS
MEV RANGE
NECK
PATIENTS
PROSTATE
PROTON BEAMS
RADIOTHERAPY
BEAMS
BODY
CARCINOMAS
CHARGED PARTICLES
DIGESTIVE SYSTEM
DISEASES
ENERGY RANGE
EPITHELIOMAS
EVALUATION
GLANDS
IONS
MALE GENITALS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEON BEAMS
ORGANS
PARTICLE BEAMS
RADIOLOGY
RESPIRATORY SYSTEM
TESTING
THERAPY